Advertisement

Amag Pharmaceuticals Inc. (Nasdaq: AMAG) reported a 39 percent spike in revenue and a 77 percent reduction in operating loss for the first nine months of the year as compared with the same time last year due to strong sales of its drug, Feraheme.

Advertisement
Advertisement